ProCE Banner Series

Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes

Join us either in-person or virtually for this dynamic CME/CE/CPE-certified interactive symposium featuring expert discussion of current guidance and emerging strategies for treating patients with early and advanced HCC and biliary tract cancers. After the symposium, view the on-demand webcast and download the associated slideset for use in your clinic.

To Register: Please click the green "Learn More" button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

For more information on ASCO's Health and Safety policy for this event, please visit ASCO's website (Health & Safety | ASCO Annual Meeting).

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Credits Available

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Physician Assistants: maximum of 1.50 hours of AAPA Category I (Preapproved) credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Registered Nurses: 1.50 Nursing contact hours

Who Should Attend

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with hepatobiliary cancers. 

All Events

Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes

Past Events

June

04

2023

7:00 PM - 8:30 PM Central Time (CT)

In-personVirtual

Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 60604

Faculty

ProCE Banner Faculty
Thomas A. Abrams, MD

Institute Physician
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

ProCE Banner Faculty
Stacey Stein, MD

Associate Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

Topics

  • Introduction and Overview
  • First- and Second-line Systemic Therapy for Advanced HCC: Current and Emerging Immunotherapy Options
  • Immunotherapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
  • BTCs: Current and Emerging Immunotherapy and Targeted Therapy Regimens
  • Audience Q&A

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Target Audience
This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with hepatobiliary cancers. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply guidelines and expert recommendations for surveillance of patients at risk of developing hepatocellular carcinoma, including the clinical application of biomarker-based surveillance
  • Integrate clinical data and consensus guidelines on the use of systemic treatment approaches into practice for patients with early-stage or intermediate-stage HCC
  • Plan evidence-based and guideline-driven individualized care for patients with advanced HCC, both in the frontline and second-line treatment settings
  • Select optimal treatment for patients with cholangiocarcinoma and other BTCs based on molecular characterization of the tumor, previous treatment, and patient characteristics and preferences
  • Identify patients with HCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with novel targeted therapies in patients with hepatobiliary cancers

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-23-035-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Attention Pharmacists:
You must complete the evaluation within 30 days of the activity for continuing pharmacy education credit to be reported to the CPE Monitor. Be sure to enter your NAPB e-profile ID and date of birth when prompted in the evaluation or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistants

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

Disclosure of Conflicts of Interest 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity.

Acknowledgement

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Supported by an educational grant from AstraZeneca.